Abstract
Rotavirus (RV) is the leading cause of severe diarrhoea in children, annually causing >500,000 diarrhoea-related deaths in children aged < 5 years worldwide.1 Since young infants can acquire the infection, there is a need for early protection.2 In addition to the substantial burden of mortality (especially in developing countries) RV gastroenteritis (RVGE) has a considerable impact on the morbidity and quality of life of both affected children and their parents in Europe.3
The RV1/monovalent vaccine is an oral G1P[8], live-attenuated human rotavirus vaccine. RV1 has a two-dose schedule that can be completed by 10 weeks of age and offers early protection against circulating RV strains. The vaccine has demonstrated efficacy against severe RVGE (90.4% [95%CI: 85.1-94.1]).4,5 Heterotypic cross-protection is the mechanism underlying the efficacy of RV1 in non-vaccine strains (79.2% [95%CI:8.9-96.5]); including the fully heterotypic G2P[4] strain.6 In trials and post-marketing surveillance (including 69 million doses), RV1 has demonstrated a clinically acceptable safety profile and has been generally well tolerated in healthy infants; furthermore, studies have shown no specific safety issues in high risk populations such as HIV-positive and pre-term infants.4,7,8
Routine RV vaccination - mainly with RV1 - was implemented in Belgium in 2006, which resulted in a 53% decrease in peak incidence by 2007, with the highest decline in children aged < 1 years (81% reduction).9 In Austria, a 74% decrease in hospitalisation rates due to RVGE was observed compared to the era before the introduction of the vaccine.10 Similar trends were also observed in US with the RV5/pentavalent bovine-human reassortant vaccine.11 New data from EuroRotaNet show the dynamic nature of rotavirus infection with the emergence of G8 and G12 strains.12,13
Widespread implementation of RV vaccination would effectively reduce the European burden of RVGE and support the WHO recommendation for its inclusion into national immunisation programmes in countries that can afford the vaccine.14
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Parashar UD, et al. J Infect Dis 2009; 200 Suppl 1: S9–S15.
Han HH, et al. 6th Annual meeting of the World Society for Pediatric Infectious Diseases (WSPID), Buenos Aires, Argentina, 18-22 November 2009; abstract.
Van der Wielen M, et al. BMC Fam Pract; 11: 22.
Ruiz-Palacios GM, et al. N Engl J Med 2006; 354: 11–22.
Vesikari T, et al. Lancet 2007; 370: 1757–63.
Neuzil K, et al. 27th European Society for Paediatric Infectious Diseases (ESPID) Brussels, Belgium, 9-13: June 2009; abstract 63.
Omenaca F, et al. 48th ICAAC/IDSA 46th annual meeting, Washington DC, October 25-28, 2008; G1–442a.
Steele D, et al. 48th ICAAC/IDSA 46th annual meeting, Washington DC, October 25-28, 2008; G1–442b.
Hanquet G, et al. 27th European Society for Paediatric Infectious Diseases (ESPID) Brussels, Belgium, 9-13: June 2009; abstract O25.
Paulke-Korinek M, et al. Pediatr Infect Dis J 2010; 29: 319–23.
CDC. MMWR Morb Mortal Wkly Rep 2008; 57: 697–700.
Aladin F, et al. J Clin Virol 2010; 47: 340–4.
Iturriza-Gomara M, et al. J Infect Dis 2009; 200 Suppl 1: S215–21.
World Health Organization. Wkly Epidemiol Rec 2009; 84: 220–36.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huppertz, HI. 6 The Importance of Rotavirus Disease Prevention in Europe. Pediatr Res 68 (Suppl 1), 4–5 (2010). https://doi.org/10.1203/00006450-201011001-00006
Issue date:
DOI: https://doi.org/10.1203/00006450-201011001-00006
